Farrow Kathryn N, Steinhorn Robin H
Department of Pediatrics, Division of Neonatology, Northwestern University Feinberg School of Medicine, 310 E. Superior St., Morton 4-685D, Chicago, IL 60611, USA.
Handb Exp Pharmacol. 2011(204):251-77. doi: 10.1007/978-3-642-17969-3_11.
Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration syndrome, congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or congenital heart disease. Because of the heterogeneous group of disorders, the therapeutic approach and response often depends on the underlying disease. In many of these conditions, there is evidence that cyclic nucleotide signaling and specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class of pulmonary vasodilators in adults. Studies are now under way to evaluate the utility, efficacy, and safety of such therapies in infants with pulmonary hypertension.
新生儿肺动脉高压与多种潜在问题相关，如呼吸窘迫综合征、胎粪吸入综合征、先天性膈疝、支气管肺发育不良、败血症或先天性心脏病。由于这类疾病具有异质性，治疗方法和反应往往取决于潜在疾病。在许多这些病症中，有证据表明环核苷酸信号传导，特别是磷酸二酯酶（PDEs）受到破坏。PDE抑制剂是成人中一类新兴的肺血管扩张剂。目前正在进行研究，以评估此类疗法在患有肺动脉高压的婴儿中的效用、疗效和安全性。
